Substantial efforts needed to help people with HIV achieve durable viral suppression, study suggests

Among people with HIV worldwide who are receiving antiretroviral therapy (ART), adults are getting closer to the global target of 95% achieving viral suppression, but progress among children and adolescents is lagging and long-term viral suppression among all groups remains a challenge. These findings of a study funded by the National Institutes of Health suggest that substantial efforts are needed to help people with HIV durably suppress the virus. The findings were published today in the journal The Lancet HIV.

People with HIV who achieve viral suppression protect their immune health and prevent transmitting HIV to others. In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set a goal of 95% of all people with HIV who are taking ART achieving viral suppression by 2030.

Scientists from the National Institutes of Health-funded International epidemiology Databases to Evaluate AIDS (IeDEA) consortium set out in 2020 to estimate how close the world is to achieving that goal. The study was led by Win Min Han, M.B.B.S., M.Sc., a Ph.D. student-researcher at the Kirby Institute of the University of New South Wales in Sydney, Australia; Azar Kariminia, Ph.D., a senior lecturer at the Kirby Institute; and Matthew G. Law, Ph.D., head of the Biostatistics and Databases Program and professor of biostatistics at the Kirby Institute.  Funding for IeDEA comes from the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, and from eight other NIH institutes and centers.

The investigators analyzed data from 148 IeDEA treatment sites in 31 countries on five continents to estimate the proportions of children, adolescents and adults who were virally suppressed one, two and three years after initiating ART. The data came from more than 21,500 children and adolescents with HIV aged 17 years or younger and more than 255,000 adults with HIV, all of whom had begun receiving ART between 2010 and 2019. Viral suppression was defined as having fewer than 1,000 copies of HIV per milliliter of blood.

The researchers calculated the percentages of children and adults who were virally suppressed based on data from those who were alive, in follow-up, and had viral load measurements for up to three years of ART. To further estimate viral suppression among people who had fallen out of HIV care during a three-year interval, the investigators looked to a Zambian study of viral suppression rates in a similar population and calculated an adjustment to viral suppression rates in the IeDEA population.

The researchers estimated that among adults, 79% were virally suppressed after one year of ART, 72% after two years and 65% after three years. Among children and adolescents, 64% were virally suppressed after one year of ART, 62% after two years and 59% after three years. These viral suppression rates illustrate how much farther global HIV treatment programs need to go to reach and sustain the UNAIDS 2030 targets, according to the investigators. Importantly, the even lower rates of viral suppression among children and adolescents with HIV underscore the need to improve approaches for achieving durable viral suppression in these age groups.

Source:
Journal reference:

Han, W.M., et al. (2021) Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. The Lancet HIV. doi.org/10.1016/S2352-3018(21)00265-4.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus